Information on Specific Types of Emergencies

DTPA (Diethylenetriamine pentaacetate)

Button Radiation Health Information for Specific Groups

What is DTPA (Diethylenetriamine pentaacetate)?

DTPA (Diethylenetriamine pentaacetate) is a medicine that can bind to radioactive plutonium, americium, and curium to decrease the amount of time it takes to get radioactive plutonium, americium, and curium out of the body.

DTPA cannot bind all of the radioactive plutonium, americium, and curium that might get into a person's body after a radiation emergency.

DTPA cannot prevent radioactive plutonium, americium, and curium from entering the body.

How does DTPA work?

DTPA comes in two forms: calcium (Ca-DTPA) and zinc (Zn-DTPA). Both forms work by tightly binding to radioactive plutonium, americium, and curium. These radioactive materials (bound to DTPA) are then passed from the body in the urine.

DTPA works best when given shortly after radioactive plutonium, americium, and curium have entered the body. The more quickly radioactive material is removed from the body, the fewer and less serious the health effects will be.

When given within the first day after internal contamination has occurred, Ca-DTPA is more effective than Zn-DTPA. After 24 hours have passed, Ca-DTPA and Zn-DTPA are equally effective.

After 24 hours, DTPA binds less effectively to radioactive plutonium, americium, and curium. However, DTPA can still work to remove these radioactive materials from the body several days or even weeks after a person has been internally contaminated.

Who can take DTPA?

Doctors and public health authorities will work together to decide who likely will benefit from DTPA treatment.

For doctors who may be administering DTPA for patients, use the following guidelines:

Infants (including breastfed infants) and children less than 12 years of age can be given either Ca-DTPA or Zn-DTPA.
- The dosage of DTPA should be based on the child's size and weight.
- The safety and effectiveness of the inhaled route of DTPA has not been studied in children.
Young adults and adults internally contaminated with plutonium, americium, or curium should receive Ca-DTPA if treated within the first 24 hours after contamination. After 24 hours, if additional treatment is needed, adults should receive Zn-DTPA. If Zn-DTPA is not available, patients may receive Ca-DTPA together with a vitamin and mineral supplement that contains zinc.
Pregnant women should be treated with Zn-DTPA, unless the woman has very high levels of internal contamination with plutonium, americium, or curium.
- Ca-DTPA should be used in pregnant women only to treat very high levels of internal radioactive contamination.
- In this case, doctors and public health authorities may prescribe a single dose of Ca-DTPA, together with a vitamin and mineral supplement that contains zinc, as the first treatment.
- After the first dose of Ca-DTPA, treatment should continue 24 hours later with a daily dose of Zn-DTPA, as needed.
Breastfeeding women who are internally contaminated with plutonium, americium, or curium can be treated with Ca-DTPA or Zn-DTPA.

How is DTPA given?

DTPA can be injected directly into a vein in the arm or dripped into a vein from a bag (intravenously [IV]).

Adults who have inhaled plutonium, americium, or curium can be treated with DTPA mist that is breathed into the lungs.

Inhaling DTPA might cause some people, especially those with asthma, to cough or wheeze.
The safety and effectiveness of inhaled DTPA has not been shown in children.

DTPA should be taken only as long as needed, as determined by a doctor.

Doctors might collect samples of blood, urine, and feces during DTPA treatment. These samples can tell the doctors how much radioactivity you are passing and how much remains in your body.

The length of treatment with DTPA will depend on:

The amount of radioactive material in your body
How well your body gets rid of the radioactive material with the help of DTPA.

What are the side effects of DTPA?

People who are given repeat doses of Ca-DTPA within a short period of time may have nausea, vomiting, diarrhea, chills, fever, itching, and muscle cramps.

Other side effects may include headache, light-headedness, chest pain, and a metallic taste in the mouth.

Ca-DTPA should be used cautiously in patients with a blood disease called hemochromatosis.

Ca-DTPA (and Zn-DTPA) bind to important minerals that the body needs (zinc, magnesium, and manganese). As a precaution, patients receiving long-term treatment with DTPA should be given a vitamin and mineral supplement that contains zinc.